Table 4.
Multivariable linear regression analysis of effect of baseline characteristics on HAQ-DI score progression at 1 year
| B | 95% CI for B | p value | |
|---|---|---|---|
| Constant | − 0.16 | − 0.51, 0.20 | 0.389 |
| HAQ-DI score at baseline | − 0.15 | − 0.27, − 0.04 | 0.009 |
| Age at onset of RP | − 0.002 | − 0.01, 0.004 | 0.518 |
| Male gender | 0.02 | − 0.18, 0.22 | 0.834 |
| mRSS | 0.01 | 0.0001, 0.03 | 0.048 |
| Immunomodulator treatment | 0.02 | − 0.17, 0.20 | 0.870 |
| Corticosteroids > 10 mg/day | 0.12 | − 0.77, 1.01 | 0.791 |
| Advanced organ involvementa | − 0.15 | − 0.67, 0.37 | 0.575 |
| Advanced lung involvement | 0.05 | − 0.55, 0.65 | 0.866 |
| Advanced cardiac involvement | 0.62 | − 0.36, 1.60 | 0.213 |
| Advanced GI involvementb | 0.40 | − 0.20, 0.99 | 0.186 |
| Advanced renal involvement | 0.47 | − 0.56, 1.50 | 0.367 |
| Esophageal symptoms | 0.33 | 0.14, 0.52 | 0.001 |
| Stomach symptoms | − 0.04 | − 0.25, 0.16 | 0.670 |
| Intestinal symptoms | 0.09 | − 0.09, 0.26 | 0.335 |
CI confidence interval, GI gastrointestinal, HAQ-DI Health Assessment Questionnaire-Disability Index, mRSS modified Rodnan Skin Score, RP Raynaud’s phenomenon
aInvolved organs coded as 0 = none, 1 = one organ involvement, 2 = multiple organ involvement
bMalabsorption or ≥ 10% weight loss from baseline